Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in adverse events compared with standard interferon (low certainty).
The review found no eligible studies for this question.
Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
The review found no eligible studies for this question.
Interferon may leads to higher adverse events (proportion) (4 to 6 months) compared with no intervention (low certainty).
Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).
Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).
Type I Interferons may leads to higher withdrawals due to adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
The review found no eligible studies for this question.